Last checked at 5 Jun 2023 10:00
Tristel plc
("Tristel" or the "Company")
Analyst and Investor presentation
Re. news of FDA De Novo approval for Tristel ULT as a high level disinfectant
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that the Company will hold a presentation for analysts and investors following this morning's announcement that Tristel ULT was approved by the FDA as a high level disinfectant for use on endocavity ultrasound probes and skin surface transducers.
Paul Swinney, CEO, and Liz Dixon, CFO, will provide details of the Company's North America Commercial Strategy in a presentation which is open to all existing and potential shareholders, as well as analysts.
The live presentation will take place on the Investor Meet Company platform at 4.30pm today, Monday 5 June 2023, and a replay facility will also be available shortly afterwards. Questions can be submitted at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Tristel plc to register for the presentation via: https://www.investormeetcompany.com/tristel-plc/register-investor
For further information please contact:
Tristel plc | Tel: 01638 721 500 | |
Paul Swinney, Chief Executive Officer | ||
Liz Dixon, Chief Financial Officer | ||
| ||
Walbrook PR Ltd | Tel: 020 7933 8780 or tristel@walbrookpr.com | |
Paul McManus | Mob: 07980 541 893 | |
Lianne Applegarth | Mob: 07584 391 303 | |
finnCap | Tel: 020 7220 0500 | |
Geoff Nash/ Charles Beeson (Corporate Finance) | ||
Alice Lane (ECM) | ||